Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Merck KGaA, F-star Alpha Strike Deal

Merck KGaA struck a deal worth up to €1 billion to acquire five bispecific immuno-oncology antibodies from F-star Alpha.

Read More »

Biogen Spinoff Bioverativ Buying True North

Bioverativ is buying True North Therapeutics for an upfront payment of $400 million and up to $425 million in milestones.

Read More »

Biogen Acquires Remedy Pharmaceuticals’ Cirara

Remedy Pharmaceuticals announced that Biogen completed an asset purchase of its Phase 3 candidate, Cirara.

Read More »

Thermo Fisher Scientific acquires Patheon

Thermo Fisher Scientific Inc. snapped up North Carolina-based Patheon N.V. in a deal valued at $7.2 billion.

Read More »

Germany’s Fresenius Kabi Slams Down $4.3 Billion for Akorn in U.S. Expansion

Germany-based Fresenius Kabi, part of Fresenius SE & Co. KGaA, slapped down $4.3 billion to acquire Illinois-based Akorn Inc. and a larger toehold in the United States.

Read More »

Becton Dickinson to acquire Bard for $24 billion

U.S. medical equipment supplier Becton Dickinson and Co. will acquire C. R. Bard Inc. in a $24 billion cash-and-stock deal, adding Bard’s devices to its portfolio in the high-growth sectors of oncology and surgery, both companies said.

Read More »

J&J first-quarter 2017 revenue misses estimates

Johnson & Johnson reported disappointing pharmaceutical and consumer product sales for first-quarter 2017 as revenue missed analyst estimates.

Read More »

Abbott, Alere End Merger Legal Battle

Abbott Laboratories and Alere Inc. have come to an accord. Illinois-based Abbott will acquire Alere for an amount less than the initially agreed upon $5.8 billion.

Read More »

Stada Accepts $5.6 Billion Takeover Offer

After weeks of bidding and speculation, German-based Stada Arzneimittel AG accepted a $5.6 billion takeover bid from Bain Capital and Cinven Partners LLP.

Read More »

Astellas Takes Out Belgium Biotech in Deal Worth $853 Million

Astellas Pharma struck a deal valued at up to $853 million to acquire Belgium-based Ogeda SA, a privately held clinical-stage drug discovery company, and its lead drug candidate fezolinetant.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom